Unicycive Therapeutics, Inc. Common Stock UNCY
i
Market datapartial · fetched 2026-11-13T19:11:07.368Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-12-18
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-13T19:10:08.555872693Z
FundamentalsAlpha Vantage · unavailable
Unicycive Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | 4.93 | 122.7% | 42.4% | |||
| 30Δ | 4.72 | 145.5% | 40.8% | |||
| 35Δ | 4.50 | 168.4% | 39.1% | |||
| 40Δ | 4.29 | 191.2% | 37.5% | |||
| 45Δ | 4.08 | 214.1% | 35.9% | |||
| 50Δ | 3.86 | 236.9% | 34.3% | |||
| 55Δ | 3.65 | 259.8% | 32.7% | |||
| 60Δ | 3.43 | 282.6% | 31.1% | |||
| 65Δ | 3.22 | 305.5% | 29.5% | |||
| 70Δ | 3.00 | 328.3% | 27.9% | |||
| 75Δ | 2.79 | 351.2% | 26.3% | |||
| 80Δ | 2.57 | 374.0% | 24.7% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- 4.93
- IV
- 122.7%
- B/E move
- 42.4%
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- 4.72
- IV
- 145.5%
- B/E move
- 40.8%
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- 4.50
- IV
- 168.4%
- B/E move
- 39.1%
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- 4.29
- IV
- 191.2%
- B/E move
- 37.5%
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- 4.08
- IV
- 214.1%
- B/E move
- 35.9%
- Pseudo strike
- IV
- B/E move
50Δ
- Pseudo strike
- 3.86
- IV
- 236.9%
- B/E move
- 34.3%
- Pseudo strike
- IV
- B/E move
55Δ
- Pseudo strike
- 3.65
- IV
- 259.8%
- B/E move
- 32.7%
- Pseudo strike
- IV
- B/E move
60Δ
- Pseudo strike
- 3.43
- IV
- 282.6%
- B/E move
- 31.1%
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- 3.22
- IV
- 305.5%
- B/E move
- 29.5%
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- 3.00
- IV
- 328.3%
- B/E move
- 27.9%
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- 2.79
- IV
- 351.2%
- B/E move
- 26.3%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 2.57
- IV
- 374.0%
- B/E move
- 24.7%
- Pseudo strike
- IV
- B/E move
Options history
No recorded observations
Biotechnology
UPB
Description unavailable
More →URGN
UroGen Pharma Ltd (URGN) is an innovative biotechnology company focused on the development of advanced therapies for urological diseases, including urothelial carcinoma and…
More →VANI
Description unavailable
More →VCEL
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cell therapies for the sports medicine and severe burn care…
More →VERA
Description unavailable
More →VERU
Veru Inc., an oncology biopharmaceutical company, focuses on the development of drugs for the treatment of cancers. The company is headquartered in Miami, Florida.
More →